Developing fractionation – the new wave in cardiac electrophysiology
An electronic medical device, including operating and
data analysis software, is being developed by
Paced electrogram fractionation analysis (PEFA) is a novel, invasive, electrophysiological technique which improves risk prediction significantly, as is evidenced by a large body of published work. It has the potential to reduce ICD (implantable cardioverter defibrillator) costs which currently run into £billions by more accurately targeting those who would benefit from ICD implantation, and with the potential to save patients currently ruled out by less accurate methods of risk stratification.
Medilec’s PEFA process has been clinically trialed in one disease, Hypertrophic Cardiomyopathy and studied in over 600 patients with a variety of diseases, including 76 patients who have survived a VF arrest from which they were resuscitated. PEFA may improve significantly on the predictive accuracy of currently available techniques. Hence the adoption of this technique would better target those who should receive ICD’s – leading to the saving of more lives and the reduction of costs and medical consequences for patients who would otherwise have inappropriate ICD implantations.
Medilec’s Managing Group comprises: Mr Robert Dixon
(Chairman: ex Hollister
Europe, Coloplast A/S, Vickers Medical and Johnson & Johnson); Dr
More detailed information is available here. For enquiries, please contact:
Tel: +44 (0)1404 42455
Fax: +44 (0)1404 41455